Clinical Trials Logo

Venous Thrombosis clinical trials

View clinical trials related to Venous Thrombosis.

Filter by:

NCT ID: NCT03251963 Completed - Surgery Clinical Trials

Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients

Start date: September 15, 2017
Phase: Phase 2
Study type: Interventional

The aim of this research is to better understand how patient-level factors can be used to predict the appropriate enoxaparin dose to maximize venous thromboembolism (VTE) risk reduction and minimize bleeding.

NCT ID: NCT03212365 Completed - Clinical trials for Venous Thromboembolism

Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery

Start date: July 3, 2017
Phase: Phase 2
Study type: Interventional

Plastic and reconstructive surgeons consistently create large, raw surfaces as part of their operative procedures. Thus, plastic & reconstructive surgery patients are among those at highest risk for anticoagulant-associated bleeding adverse drug events (ADEs). This study seeks to optimize both the safety and effectiveness of post-operative enoxaparin by comparing aFXa levels, bleeding events, and VTE events among plastic & reconstructive surgery patients randomized to receive two different enoxaparin dose regimens.

NCT ID: NCT03201367 Completed - Clinical trials for Portal Vein Thrombosis

Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV

Start date: May 1, 2014
Phase: N/A
Study type: Interventional

Portal vein thrombosis (PVT) in patients with liver cirrhosis may be due to neoplastic growth or non-neoplastic causes. - Treating PVT with anticoagulation in liver cirrhosis is difficult to be established but may be of great benefit in acute symptomatic PVT. - The ultimate goal is complete recanalization of the portal vein without inducing major bleeding, abnormal liver function tests or increased mortality.

NCT ID: NCT03178864 Completed - Clinical trials for Cerebral Venous Thrombosis

Study of Rivaroxaban for CeREbral Venous Thrombosis

SECRET
Start date: March 12, 2019
Phase: Phase 2
Study type: Interventional

SECRET examines the safety of rivaroxaban versus standard-of-care for treatment of symptomatic cerebral venous thrombosis, initiated within 14 days of diagnosis.

NCT ID: NCT03148548 Completed - Clinical trials for Iliac Vein Thrombosis

Substudy - Evaluation of Patients With Iliac Vein Thrombosis

Start date: November 2016
Phase:
Study type: Observational [Patient Registry]

Patients with previous diagnosis of iliac vein thrombosis are enrolled in this registry. Using standardized questionnaire, clinical data detailing venous thromboembolism and contributing VTE risk factors are recorded. Results of technical and laboratory investigations including screening of thrombophilic disorders were additionally entered into the database.

NCT ID: NCT03141749 Completed - Pulmonary Embolism Clinical Trials

Venous Thromboembolism in DM1

DM1-VTE
Start date: January 2000
Phase: N/A
Study type: Observational

The risk for venous thromboembolism (VTE) in DM1 and in other inherited myopathies, which can lead to chronic immobilization, are unknown. The purpose of this study is to evaluate incidence of VTE in cohort of patients presenting with DM1 with a comparison to a group of other inheritable myopathies and to a community-based population.

NCT ID: NCT03124654 Completed - Atrial Fibrillation Clinical Trials

Development of a Questionnaire to Assess Patient Knowledge About Non-vitamin K Anticoagulants (NOAC)

Start date: September 1, 2016
Phase: N/A
Study type: Observational

Pharmacists are in the best position to counsel and educate patients on anticoagulant agents such as NOACs. This should enable patients to play a more active role in their treatment and ultimately enhance adherence behaviour. However, educational elements should be targeted to knowledge. Thus, the investigators will develop and validate a questionnaire that can assess knowledge about NOACs

NCT ID: NCT03089255 Completed - Pulmonary Embolism Clinical Trials

Assessment of the Impact of TIP Score on Thromboprophylaxis in Patients With Non-surgical Lower Leg Trauma.

EvaTIP
Start date: April 3, 2017
Phase:
Study type: Observational [Patient Registry]

Traumatic lesions are the leading causes of admission to the emergency center (39%), isolated non-surgical lower limbs trauma are in the foreground. Two recent meta-analyzes suggest the value of Low Molecular Weight Heparins (LMWH) which would reduce symptomatic Thromboembolism Events (TE) in patients with lower limb trauma. However, many recent studies conclude to the need of stratifying the TE risk according to the patient and the nature of his trauma to obtain an individualized therapeutic decision. The retrospectively established L-TRIP (cast) score allows stratification of the risk without taking into account the type of trauma. The TIP score (Trauma, Immobilization and Patient) was established by consensus of international experts via the Delphi method. We suggest that the application of the TIP score to rationalize indications of thromboprophylaxis in patients with isolated non-surgical trauma of a lower limb should reduce the rate of anticoagulation prescription without increasing the risk of symptomatic thromboembolic complications with a direct benefit for patients and medico-economic for the society.

NCT ID: NCT03075761 Completed - Clinical trials for Deep Vein Thrombosis

Physical Activity in Children at Risk of Post-thrombotic Sequelae (PACT)

PACT
Start date: November 18, 2016
Phase: N/A
Study type: Interventional

'The PACT trial' is randomized pilot trial to demonstrate the feasibility and potential effectiveness of a personal "fitness tracker" to improve adherence to an activity regimen following an initial acute DVT in children.

NCT ID: NCT03068338 Completed - Clinical trials for Deep Vein Thrombosis

Robotic Sock Technology for Prevention of Deep Vein Thrombosis and Joint Contracture

Start date: February 16, 2017
Phase: N/A
Study type: Interventional

The research team's aim is to investigate the effects of the team's soft robotic socks in providing assisted ankle dorsiflexion-plantarflexion and promoting venous blood flow in stroke patients. Specifically, the investigators intend to 1) observe the development of joint contracture in terms of the range of motion of the ankle joint given the use of the device 2) monitor the presence of blood clots in the deep veins using compression Duplex ultrasonography given the use of the sock device. The investigators hypothesize that a soft robotics approach can provide compliant actuation to simulate natural ankle dorsiflexion and plantarflexion, which will consequently promote blood circulation in the lower leg of stroke patients who have not previously developed ankle joint contracture. This will prevent the occurrence of DVT and movement in the ankle joint will alleviate stiffness. This robotic sock intervention is to prevent the development of ankle joint contracture so established ankle contractures will be excluded from this study.